Adjuvant treatment of postmenopausal women w/ estrogen receptor +ve early invasive breast cancer. 1st-line treatment of postmenopausal women w/ estrogen receptor +ve or estrogen receptor unknown locally advanced or metastatic breast cancer. Advanced breast cancer in postmenopausal women w/ estrogen receptor -ve & previous +ve clinical response to tamoxifen.
Women w/ or at risk of osteoporosis. Formally assess bone mineral density by bone densitometry eg, DEXA scanning at the commencement of treatment & at regular intervals thereafter. Concomitant use w/ LHRH analogues. Recommended duration of treatment for early disease. May affect driving or operating machinery as asthenia & somnolence may occur. Not recommended use for childn.